NCT01149915: Study of Hypoxia-Activated Prodrug TH-302 to Treat Advanced Leukemias |
|
|
| Completed | 1 | 40 | US | TH-302 | Threshold Pharmaceuticals | Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, High-risk Myelodysplastic Syndrome, Chronic Lymphocytic Leukemia, Advanced Myelofibrosis | 08/13 | 08/13 | | |